Cue Biopharma Inc Book/Share
What is the Book/Share of Cue Biopharma Inc?
The Book/Share of Cue Biopharma Inc is 0.17
What is the definition of Book/Share?
Book value per share is a company’s assets minus liabilities divided by the number of shares outstanding.
mrq (most recent quarter)
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Book/Share of companies in the Health Care sector on NASDAQ compared to Cue Biopharma Inc
What does Cue Biopharma Inc do?
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
Companies with book/share similar to Cue Biopharma Inc
- Tortoise Acquisition has Book/Share of 0.17
- Orex Minerals has Book/Share of 0.17
- Netfin Acquisition has Book/Share of 0.17
- Aclaris Therapeutics Inc has Book/Share of 0.17
- ZW Data Action Technologies Inc has Book/Share of 0.17
- RTW Retailwinds has Book/Share of 0.17
- Cue Biopharma Inc has Book/Share of 0.17
- CURE Pharmaceutical has Book/Share of 0.17
- Cobra Venture has Book/Share of 0.17
- Roblox has Book/Share of 0.17
- DLC Asia has Book/Share of 0.17
- Blue Star Foods has Book/Share of 0.17
- Kingsgate Consolidated has Book/Share of 0.17